Skip to main content
SpringerLink
Log in

Genetic Polymorphisms of Surfactant Protein D rs2243639, Interleukin (IL)-1β rs16944 and IL-1RN rs2234663 in Chronic Obstructive Pulmonary Disease, Healthy Smokers, and Non-Smokers

  • Original Research Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

Background and Objectives

Chronic obstructive pulmonary disease (COPD) is a complex chronic inflammatory disease that involves the activity of various inflammatory cells and mediators. It has been suggested that susceptibility to COPD is, at least in part, genetically determined. The primary aim of this study was to investigate the association between surfactant protein D (SFTPD) rs2243639, interleukin (IL)-1β rs16944 and IL-1 receptor antagonist (IL-1RN) rs2234663 gene polymorphisms and COPD susceptibility, as well as examining the association between the various IL-1RN/IL-1β haplotypes and pulmonary function tests (PFT). Secondly, we aimed to examine the influence of SFTPD rs2243639 polymorphism on serum surfactant protein D (SP-D) level.

Methods

A total of 114 subjects were recruited in this study and divided into three groups: 63 COPD patients, 25 asymptomatic smokers, and 26 healthy controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed for the detection of SFTPD rs2243639 and IL-1β rs16944 polymorphisms. Detection of variable numbers of an 86-bp tandem repeat (VNTR) of IL-1RN was done using PCR. Serum SP-D level was measured using enzyme linked-immunosorbent assay. PFTs were measured by spirometry.

Results

Carriers of the SFTPD AG and AA polymorphic genotypes constituted 71.4 % of COPD patients versus 48 % in asymptomatic smokers, with a statistically significant difference between the two groups (p = 0.049). Smokers who were carriers of the polymorphic SFTPD rs2243639 A allele (AG and AA genotypes) have a 2.708 times risk of developing COPD when compared with wild-type GG genotype carriers [odds ratio (OR) 2.708 (95 % CI 1.041–7.047)]. Forced expiratory flow (FEF) 25–75 % predicted was higher in IL-1RN*1/*1 when compared with *1/*2 (p = 0.013). FEF25–75 % predicted in carriers of haplotype IL-1RN *1/IL-1β T (49.21 ± 10.26) was statistically significantly higher than in carriers of IL-1RN *2/IL-1β T (39.67 ± 12.64) [p = 0.005]. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) in carriers of haplotype IL-1RN *1/IL-1β T (64.09 ± 6.39) was statistically significantly higher than in carriers of IL-1RN *2/IL-1βT (59.44 ± 7.71) [p = 0.048]. There was no association between SFTPD rs2243639 genotypes and serum SP-D level.

Conclusions

Smokers who are carriers of the SFTPD AG and AA polymorphic genotypes may be at a higher risk of developing COPD when compared with wild-type GG genotype carriers. IL-1RN rs2234663/IL-1β rs16944 haplotypes influence FEF25–75 % predicted and FEV1/FVC. SFTPD rs2243639 polymorphism did not influence serum SP-D levels in our group of recruited subjects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stewart JI, Criner GJ. The small airways in chronic obstructive pulmonary disease: pathology and effects on disease progression and survival. Curr Opin Pulm Med. 2013;19(2):109–15.

    Article  CAS  PubMed  Google Scholar 

  2. ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: definitions, epidemiology, pathophysiology, diagnosis, and staging. Am J Respir Crit Care Med 1995;152:S78–S83.

    Google Scholar 

  3. Ishii T, Matsuse T, Teramoto S, et al. Neither IL-1β, IL-1 receptor antagonist, nor TNF-α polymorphisms are associated with susceptibility to COPD. Respir Med. 2000;94:847–51.

    Article  CAS  PubMed  Google Scholar 

  4. Ishii T, Hagiwara K, Kamio K, et al. Involvement of surfactant protein D in emphysema revealed by genetic association study. Eur J Hum Genet. 2012;20:230–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. McCloskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe obstruction pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med. 2001;164:1419–24.

    Article  CAS  PubMed  Google Scholar 

  6. Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol. 2005;42:279–87.

    Article  CAS  PubMed  Google Scholar 

  7. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest. 2002;109:707.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol. 2001;63:521.

    Article  CAS  PubMed  Google Scholar 

  9. Nadesalingam J, Reid KB, Palaniyar N. Collectin surfactant protein D binds antibodies and interlinks innate and adaptive immune systems. FEBS Lett. 2005;579:4449–53.

    Article  CAS  PubMed  Google Scholar 

  10. Guo CJ, Atochina-Vasserman EN, Abramova E, et al. S-nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol. 2008;6(11):e266. doi:10.1371/journal.pbio.0060266.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Gardai SJ, Xiao YQ, Dickinson M, et al. By binding SIRP alpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell. 2003;115(1):13–23.

    Article  CAS  PubMed  Google Scholar 

  12. Stahlman MT, Gray ME, Hull WM, et al. Immunolocalization of surfactant protein-D (SP-D) in human fetal, newborn, and adult tissues. J Histochem Cytochem. 2002;50:651.

    Article  CAS  PubMed  Google Scholar 

  13. Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med. 1999;159:646.

    Article  CAS  PubMed  Google Scholar 

  14. Leth-Larsen R, Nordenbaek C, Tornoe I, et al. Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia small star, filled. Clin Immunol. 2003;108:29.

    Article  CAS  PubMed  Google Scholar 

  15. Glas J, Beynon V, Bachstein B, et al. Increased plasma concentration of surfactant protein D in chronic periodontitis independent of SFTPD genotype: potential role as a biomarker. Tissue Antigens. 2008;72:21–8.

    Article  CAS  PubMed  Google Scholar 

  16. Crouch E, Rust K, Veile R, et al. Genomic organization of human surfactant protein D (SP-D). SP-D is encoded on chromosome 10q22.2–23.1. J Biol Chem. 1993;268:2976–83.

    CAS  PubMed  Google Scholar 

  17. Lin Z, Pearson C, Chinchilli V, et al. Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS. Clin Genet. 2000;58:181–91.

    Article  CAS  PubMed  Google Scholar 

  18. Shakoori TA, Sin DD, Bokhari SN, et al. SP-D polymorphisms and the risk of COPD. Dis Markers. 2012;33(2):91–100. doi:10.3233/DMA-2012-0909.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Vandivier RW, Ogden CA, Fadok VA, et al. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol. 2002;169:3978–86.

    Article  CAS  PubMed  Google Scholar 

  20. Park JW, Ryter SW, Choi AM. Functional significance of apoptosis in chronic obstructive pulmonary disease. COPD. 2007;4:347–53.

    Article  PubMed  Google Scholar 

  21. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 2009;34:95–102.

    Article  CAS  PubMed  Google Scholar 

  22. Brandolini L, Sergi R, Caselli G, et al. Interleukin-1 beta primes interleukin-8-stimulated chemotaxis and elastase release in human neutrophils via its type I receptor. Eur Cytokine Network. 1997;8:173–8.

    CAS  Google Scholar 

  23. Tsang YT, Neelamegham S, Hu Y, et al. Synergy between L-selectin signaling and chemotactic activation during neutrophil adhesion and transmigration. J Immunol. 1997;159:4566–77.

    CAS  PubMed  Google Scholar 

  24. Conca W, Kaplan PB, Krane SM. Increases in levels of procollagenase messenger RNA in cultured fibroblasts induced by human recombinant interleukin 1 beta or serum follow c-jun expression and are dependent on new protein synthesis. J Clin Invest. 1989;83:1753–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. D’Armiento J, Dalal SS, Okada Y, et al. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell. 1992;71:955–61.

    Article  PubMed  Google Scholar 

  26. Serdaroglu GS, Alpman A, Tosun A, et al. Febrile seizures: interleukin 1β and interleukin-1 receptor antagonist polymorphisms. Pediatr Neurol. 2009;40:113–6.

    Article  PubMed  Google Scholar 

  27. Kira R, Torisu H, Takemoto M, et al. Genetic susceptibility to simple febrile seizures: interleukin-1beta promoter polymorphisms are associated with sporadic cases. Neurosci Lett. 2005;384:239–44.

    Article  CAS  PubMed  Google Scholar 

  28. Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (Global strategy for diagnosis, management, and prevention of COPD). http://www.goldcopd.com/ (updated 2013). Accessed 10 Sep 2013

  29. American Thoracic Society. Standardization of spirometry. Am J Respir Crit Care Med. 1994;152:1107–36.

    Google Scholar 

  30. Alagappan R. Smoking and cardiovascular disease. In: Alagappan R, editor. Manual of practical medicine. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2002. p. 562–3.

    Google Scholar 

  31. Zhang D, Zheng H, Zhou Y, et al. Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer. 2007;7:45. doi:10.1186/1471-2407-7-45.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Barnes PJ, Celi BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165–85.

    Article  CAS  PubMed  Google Scholar 

  33. Hersh CP, DeMeo DL, Lange C, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol. 2005;33:71–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Guo X, Lin H-M, Lin Z, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J. 2001;18:482–90.

    Article  CAS  PubMed  Google Scholar 

  35. Thomas NJ, DiAngelo S, Hess JC, et al. Transmission of surfactant protein variants and haplotypes in children hospitalized with respiratory syncytial virus. Pediatr Res. 2009;66(1):70–3. doi:10.1203/PDR.0b013e3181a1d768.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Ampuero S, Luchsinger V, Tapia L, et al. SP-A1, SP-A2 and SP-D gene polymorphisms in severe acute respiratory syncytial infection in Chilean infants. Infect Genet Evol. 2011;11(6):1368–77.

    Article  CAS  PubMed  Google Scholar 

  37. Thomas NJ, Fan R, DiAngelo S, et al. Haplotypes of the surfactant protein genes A and D as susceptibility factors for the development of respiratory distress syndrome. Acta Paediatr. 2007;96:985–9.

    Article  PubMed  Google Scholar 

  38. Krueger M, Puthothu B, Gropp E, et al. Amino acid variants in surfactant protein D are not associated with bronchial asthma. Pediatr Allergy Immunol. 2006;17:77–81.

    Article  PubMed  Google Scholar 

  39. van Diemen CC, Postma DS, Aulchenko YS, et al. Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate. Eur Respir J. 2010;35:768–75. doi:10.1183/09031936.00054408.

    Article  PubMed  Google Scholar 

  40. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672–88.

    Article  CAS  PubMed  Google Scholar 

  41. Joos L, McIntyre L, Ruan J, et al. Association of IL-1beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax. 2001;56:863–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Hegab AE, Sakamoto T, Saitoh W, et al. Polymorphisms of TNFα, IL1β, and IL1RN genes in chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2005;329:1246–52.

    Article  CAS  PubMed  Google Scholar 

  43. Mei JJ, Liang Y, Shen N, He B. Association between interleukin-1B polymorphisms and chronic obstructive pulmonary disease: a meta-analysis. Zhonghua Yi Xue Za Zhi. 2013;93(12):910–5.

    CAS  PubMed  Google Scholar 

  44. Asada M, Yamaya M, Ebihara S, et al. Interleukin-1β gene polymorphisms associated with COPD. Chest. 2005;128:1072–3. doi:10.1378/chest.128.2.1072.

    Article  PubMed  Google Scholar 

  45. Danilko KV, Korytyna GF, Akhmadishina LZ, et al. Association of polymorphisms of cytokine genes (IL1B, IL1RN, TNFA, LTA, IL6, IL8, and IL10) with chronic obstructive pulmonary disease. Mol Biol. 2007;41(1):22–31.

    Article  CAS  Google Scholar 

  46. Burgel PR. The role of small airways in obstructive airway diseases. Eur Respir Rev. 2011;20(119):23–33. doi:10.1183/09059180.00010410.

    Article  PubMed  Google Scholar 

  47. Gromova AY, Simbirtsev AS. Polymorphism of human genes of the IL-1 family. Tsitokiny Vospal. 2005;4:3–12.

    Google Scholar 

  48. Jeremias J, Ledger WJ, Witkin SS. Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis. Am J Obstet Gynecol. 2000;182:283–5.

    Article  CAS  PubMed  Google Scholar 

  49. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology. 1994;106:637–42.

    CAS  PubMed  Google Scholar 

  50. Tarlow JK, Clay FE, Cork MJ, et al. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Investig Dermatol. 1994;103:387–90.

    Article  CAS  PubMed  Google Scholar 

  51. Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993;91:403–4.

    Article  CAS  PubMed  Google Scholar 

  52. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1RA) plasma levels are co-ordinately regulated by both IL-1RA and IL-1beta genes. Eur J Immunol. 1998;28:2598–602.

    Article  CAS  PubMed  Google Scholar 

  53. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995;99:303–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol. 1998;47:195–8.

    Article  CAS  PubMed  Google Scholar 

  55. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328:106–13.

    Article  CAS  PubMed  Google Scholar 

  56. Winkler C, Atochina-Vasserman EN, Holz O, et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res. 2011;12:29. doi:10.1186/1465-9921-12-29.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Ozyurek BA, Ulasli SS, Bozbas SS. Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease. Multidiscipl Respir Med. 2013;8(36):1–7.

    Google Scholar 

  58. Sørensen GL, Hjelmborg JvB, Kyvik KO, et al. Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol. 2006;290:1010–7. doi:10.1152/ajplung.00487.2005.

    Article  Google Scholar 

  59. Betsuyaku T, Kuroki Y, Nagai K, et al. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J. 2004;24:964–70.

    Article  CAS  PubMed  Google Scholar 

  60. Foreman MG, Kong X, Demeo DL, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2011;44:316–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Leth-Larsen R, Garred P, Jensenius H, et al. A common polymorphism in the SFTPD gene influences assembly, function, and concentration of surfactant protein D. J Immunol. 2005;174:1532–8.

    Article  CAS  PubMed  Google Scholar 

  62. Heidinger K, König IR, Bohnert A, et al. Polymorphisms of the human surfactant protein-D (SFTPD) gene: strong evidence that serum levels of surfactant protein-D (SP-D) are genetically influenced. Immunogenetics. 2005;57:1–7.

    Article  CAS  PubMed  Google Scholar 

  63. He Y, Crouch EC, Rust K, et al. Proximal promoter of the surfactant protein D gene: regulatory roles of AP-1, forkhead box, and GT box binding proteins. J Biol Chem. 2000;275:31051–60.

    Article  CAS  PubMed  Google Scholar 

  64. Rust K, Bingle L, Mariencheck W, et al. Characterization of the human surfactant protein D promoter: transcriptional regulation of SP-D gene expression by glucocorticoids. Am J Respir Cell Mol Biol. 1996;14:121–30.

    Article  CAS  PubMed  Google Scholar 

  65. Shakoori TA, Sin DD, Ghafoor F, et al. Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Disease Markers. 2009;27:287–94. doi:10.3233/DMA-2009-0674.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Engströma G, Lindberg C, Gerhardsson de Verdier M, et al. Blood biomarkers and measures of pulmonary function: a study from the Swedish twin registry. Respir Med. 2012;106:1250–7.

    Article  Google Scholar 

Download references

Acknowledgments and Disclosures

The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, El Saray St., El Manial, 11956, Cairo, Egypt

    Marianne Samir M. Issac

  2. Department of Chest Diseases, Faculty of Medicine, Cairo University, Cairo, Egypt

    Wafaa Ashur & Heba Mousa

Authors
  1. Marianne Samir M. Issac
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wafaa Ashur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heba Mousa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marianne Samir M. Issac.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 173 kb)

Supplementary material 2 (DOCX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Issac, M.S.M., Ashur, W. & Mousa, H. Genetic Polymorphisms of Surfactant Protein D rs2243639, Interleukin (IL)-1β rs16944 and IL-1RN rs2234663 in Chronic Obstructive Pulmonary Disease, Healthy Smokers, and Non-Smokers. Mol Diagn Ther 18, 343–354 (2014). https://doi.org/10.1007/s40291-014-0084-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-014-0084-5

Keywords

Search

Navigation